Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/29243
DC FieldValueLanguage
dc.contributor.authorJara-Palomares L,en_US
dc.contributor.authorOtero R,en_US
dc.contributor.authorJimenez D,en_US
dc.contributor.authorCarrier M,en_US
dc.contributor.authorTzoran I,en_US
dc.contributor.authorBrenner B,en_US
dc.contributor.authorMargeli M,en_US
dc.contributor.authorPraena-Fernandez JM,en_US
dc.contributor.authorGrandone E,en_US
dc.contributor.authorMonreal Men_US
dc.contributor.authorRIETE Investigatorsen_US
dc.contributor.authorBosevski Men_US
dc.contributor.authorZdraveska Men_US
dc.date.accessioned2024-02-09T09:32:08Z-
dc.date.available2024-02-09T09:32:08Z-
dc.date.issued2016-
dc.identifier.citationJara-Palomares L, Otero R, Jimenez D, Carrier M, Tzoran I, Brenner B, Margeli M, Praena-Fernandez JM, Grandone E, Monreal M; RIETE Investigators (Bosevski M, Zdraveska M). Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. Chest. 2017 Mar;151(3):564-571. doi: 10.1016/j.chest.2016.10.025. Epub 2016 Nov 1. PMID: 27815153.en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12188/29243-
dc.description.abstractBackground: The benefits of a diagnostic workup for occult cancer in patients with VTE are controversial. Our aim was to provide and validate a risk score for occult cancer in patients with VTE. Methods: We designed a nested case-control study in a cohort of patients with VTE included in the RIETE (Registro Informatizado Enfermedad TromboEmbólica) registry from 2001 to 2014. Cases included cancer detected beyond the first 30 days and up to 24 months after VTE. Control subjects were defined as patients with VTE with no cancer in the same period. Results: Of 5,863 eligible patients, 444 (7.6%; 95% CI, 6.8%-8.2%) were diagnosed with occult cancer. On multivariable analysis, variables selected were male sex, age > 70 years, chronic lung disease, anemia, elevated platelet count, prior VTE, and recent surgery. We built a risk score assigning points to each variable. Internal validity was confirmed using bootstrap analysis. The proportion of patients with cancer who scored ≤ 2 points was 5.8% (241 of 4,150) and that proportion in those who scored ≥ 3 points was 12% (203 of 1,713). We also identified scores divided by sex and age subgroups. Conclusions: This is the first risk score that has identified patients with VTE who are at increased risk for occult cancer. Our score needs to be externally validated.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofChesten_US
dc.subjectneoplasmen_US
dc.subjectpulmonary embolismen_US
dc.subjectrisken_US
dc.subjectvenous thromboembolismen_US
dc.titleDevelopment of a Risk Prediction Score for Occult Cancer in Patients With VTEen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.chest.2016.10.025-
item.grantfulltextopen-
item.fulltextWith Fulltext-
crisitem.author.deptFaculty of Medicine-
crisitem.author.deptFaculty of Medicine-
Appears in Collections:Faculty of Medicine: Journal Articles
Files in This Item:
File Description SizeFormat 
2017,jara-palomares, ocult cancer.pdf1.24 MBAdobe PDFView/Open
Show simple item record

Page view(s)

17
checked on May 13, 2024

Download(s)

1
checked on May 13, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.